【翰森制药(03692.HK):注射用HS-20197获国家药品监督管理局签发的药物临床试验批准通知书】智通财经APP讯,翰森制药(03692.HK)发布公告,于2026年9月11日,本集团自主研发的1类新药注射用
HS-20197获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书,拟用于开展“晚期实体瘤”的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.